Hexagon Nutrition Limited is launching its Initial Public Offering on June 5, 2026, marking a significant milestone in the company's public market debut. The nutrition sector company has set the price band at ₹42-45 per share and plans to raise ₹139 crore through an Offer for Sale. According to The Economic Times, the issue will close on June 9, 2026, providing investors with a structured timeline for participation in this public offering. The company's equity shares will make their secondary market debut on June 12, 2026 on both BSE and NSE. As per investorgain.com, the grey market premium (GMP) stands at zero, indicating that shares are currently expected to list around the issue price.
The ₹139 crore fundraising target through the Offer for Sale structure indicates the company's capital requirements for its next phase of growth and expansion plans. Since there is no fresh issuance component, the firm will not receive any proceeds from the issue, with all money raised going to selling shareholders. The ₹42-45 price band represents the company's initial public offering structure, as reported by The Economic Times. The structured timeline from June 5 to June 9, 2026, provides adequate time for investor evaluation and subscription processes, with the basis of allotment expected to be finalised on June 10, 2026. The public issue comprises only an offer for sale of up to 30.86 million equity shares with selling shareholders including promoters Arun Purushottam Kelkar, Subhash Purushottam Kelkar, Aditya Kelkar and Nutan Subhash Kelkar.
The anchor investor round will occur on Thursday, June 4, 2026, according to the red herring prospectus (RHP). The issue is solely an offer for sale of 30,859,704 shares valued at ₹139 crore, with selling shareholders including promoters Arun Purushottam Kelkar, Aditya Kelkar, Subhash Purushottam Kelkar and Nutan Subhash Kelkar. The company has set aside 50% of the net issue for qualified institutional buyers, 35% for retail investors, and the remaining 15% for non-institutional investors. The least investment for a retail individual investor is 333 shares and multiples thereof, with Cumulative Capital and Catalyst Capital Partners serving as book-running lead managers and KFin Technologies as the registrar. Investors can bid for a minimum of 333 shares, requiring an investment of ₹14,985 at the upper end of the price band.
Hexagon Nutrition is a differentiated and research-orientated pure-play nutrition firm that offers a comprehensive range of products, including micronutrient premixes and therapeutic and clinical products, as reported by The Economic Times. The company operates two dedicated in-house R&D facilities at Nasik and Chennai, positioning it as a research-driven nutrition company. Founded in 1993, Hexagon Nutrition operates as a research-driven nutrition company with a portfolio spanning micronutrient premixes, therapeutic nutrition products and clinical nutrition offerings. The nutrition sector's focus on health and wellness products aligns with current market trends, potentially attracting investor interest in the IPO process.
Hexagon Nutrition's IPO offers investors exposure to India's growing nutrition, wellness and micronutrient market, but comes with several key risks that investors should carefully evaluate. According to the RHP, the company derives a significant portion of its revenue from premix formulations, contributing ₹1,377.26 million or 51.47% of revenue during the nine months ended December 31, 2025. Key risks include heavy dependence on foreign exchange fluctuations given operations across more than 70 countries, exposure to overseas operations with subsidiaries in Uzbekistan, South Africa and China, and loss-making foreign subsidiaries that may require additional capital support. The company also faces manufacturing facility concentration risk with four facilities and dependence on raw material availability for vitamins, whey protein and other ingredients. Despite improved profitability with PAT margins rising from 2.07% in FY23 to 9.81% during the nine months ended December 2025, the company cautions that these gains may not continue indefinitely.
